NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE6791 Query DataSets for GSE6791
Status Public on May 15, 2007
Title Gene Expression Profiles of HPV-Positive and -Negative Head/Neck and Cervical Cancers
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Human papillomaviruses (HPVs) are associated with nearly all cervical cancers (CCs), 20-30% of head and neck cancers (HNCs), and other cancers. Because HNCs also arise in HPV-negative patients, this type of cancer provides unique opportunities to define similarities and differences of HPV-positive versus HPV-negative cancers arising in the same tissue. Here, we describe genome-wide expression profiling of 84 HNCs, CCs and site-matched normal epithelial samples in which we used laser capture microdissection to enrich samples for tumor-derived versus normal epithelial cells. This analysis revealed that HPV+HNCs and CCs differed in their patterns of gene expression yet shared many changes compared to HPV-HNCs. Some of these shared changes were predicted, but many others were not. Notably, HPV+HNCs and CCs were found to be upregulated in their expression of a distinct and larger subset of cell cycle genes than observed in HPV-HNC. Moreover, HPV+ cancers over-expressed testis-specific genes that are normally expressed only in meiotic cells. Many, though not all, of the hallmark differences between HPV+HNC and HPV-HNC were a direct consequence of HPV and in particular the viral E6 and E7 oncogenes. This included a novel association of HPV oncogenes with testes specific gene expression. These findings in primary human tumors provide novel biomarkers for early detection of HPV+ and HPV- cancers, and emphasize the potential value of targeting E6 and E7 function, alone or combined with radiation and/or traditional chemotherapy, in the treatment of HPV+ cancers.
Keywords: Gene expression ptofiles of primary cancers
 
Overall design All tissue samples were fresh frozen in liquid nitrogen and collected with patients’ consent under approval of the Institutional Review Boards from all participating institutions. Each tissue sample was cryosectioned, and selected sections stained with hematoxylin/eosin, and reviewed to determine tumor content, pathological status, and freedom from necrosis and freezing artifacts. Epithelial cells from all normal samples and tumor cells from HNC or CC samples with less than 80% tumor were laser capture microdissected from adjacent sections using a PixCell II LCM system. For guidance, an adjacent section was briefly stained with hematoxylin to visualize tissue structure. Total RNA was extracted from sectioned and/or microdissected samples as follows: 1 ml of TRIzol (Invitrogen, Carlsbad, CA) was added to each tissue sample, homogenized by passing through a 20 gauge needle, and added to 0.2 ml chloroform. After centrifugation at 20,000 xg for 20 min at 4oC, RNA in the aqueous phase was precipitated with an equal volume of isopropanol for 30 min at 4oC, pelleted, and washed twice with cold 70% ethanol. Double strand (ds) cDNA was synthesized from this RNA using a SuperScript ds cDNA synthesis kit (Invitrogen) and T7 promoter-linked oligo (dT)24. Complementary RNA (cRNA) was synthesized from T7 promoter-linked ds cDNA using a MEGAscript high transcription kit (Ambion, Austin, TX). To obtain a sufficient cRNA for 2 microarray hybridizations, this amplification process was repeated. Second round cRNA was biotin labeled using a BioArray High Yield RNA Transcript Labeling Kit (Enzo Life Sciences, Farmingdale, NY) and stored at -80oC until hybridized. cRNA quality and quantity was determined by gel electrophoresis and UV spectrophotometry. Whole human gene expression was profiled using Affymetrix Human Genome U133 Plus 2.0 arrays.
 
Contributor(s) Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ, Connor JP, Haugen TH, Smith EM, Kelsey KT, Turek LP, Ahlquist P
Citation(s) 17510386
Submission date Jan 18, 2007
Last update date Feb 26, 2020
Contact name Paul Ahlquist
E-mail(s) [email protected]
Organization name University of Wisconsin-Madison
Department Oncology
Street address 1525 Linden Dr.
City Madison
State/province WI
ZIP/Postal code 53706
Country USA
 
Platforms (1)
GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Samples (84)
GSM155645 CC010
GSM155646 CC028
GSM155647 CC029
Relations
BioProject PRJNA99227

Patient information header descriptions
Tissue ID
Case
Source
HPV
LCM
Anatomical sites
Gender
Age
Histological grade
Stage
Metastasis
Accession number

Data table
Tissue ID Case Source HPV LCM Anatomical sites Gender Age Histological grade Stage Metastasis Accession number
CC010 Cervical cancer Gynecologic Oncology Group + (31) Yes Cervix Female 35 Well/moderately II No GSM155645
CC028 Cervical cancer Gynecologic Oncology Group + (16) No Cervix Female 27 Well/moderately IB2 Yes GSM155646
CC029 Cervical cancer Gynecologic Oncology Group + (18) Yes Cervix Female 40 Well/moderately IB No GSM155647
CC034A Cervical cancer Gynecologic Oncology Group + (18) Yes Cervix Female 42 Poorly/undiffer IB No GSM155648
CC034B Cervical cancer Gynecologic Oncology Group + (58) No Cervix Female 44 Poorly/undiffer II/III No GSM155649
CC068 Cervical cancer Gynecologic Oncology Group + (35) No Cervix Female 41 Poorly/undiffer IB Yes GSM155650
CC205 Cervical cancer Gynecologic Oncology Group + (16) Yes Cervix Female 57 Well/moderately IB No GSM155651
CC225 Cervical cancer Gynecologic Oncology Group + (16) Yes Cervix Female 44 Well/moderately IV ND** GSM155652
CC233 Cervical cancer Gynecologic Oncology Group - Yes Cervix Female 44 Well/moderately IB No GSM155653
CC237 Cervical cancer Gynecologic Oncology Group + (16) No Cervix Female 25 Well/moderately IB No GSM155654
CC243 Cervical cancer Gynecologic Oncology Group - No Cervix Female 30 Poorly/undiffer IB2 No GSM155655
CC300 Cervical cancer Gynecologic Oncology Group + (18) Yes Cervix Female 47 Poorly/undiffer IB2 No GSM155656
CC304 Cervical cancer Gynecologic Oncology Group + (33) No Cervix Female 63 Poorly/undiffer IB No GSM155657
CC437 Cervical cancer Gynecologic Oncology Group + (16) No Cervix Female 38 Poorly/undiffer IB No GSM155658
CC507 Cervical cancer Gynecologic Oncology Group + (16) No Cervix Female 52 Poorly/undiffer IIIB Yes GSM155659
CC515 Cervical cancer Gynecologic Oncology Group + (16) Yes Cervix Female 38 Poorly/undiffer IB2 No GSM155660
CC519 Cervical cancer Gynecologic Oncology Group + (16) Yes Cervix Female 48 Well/moderately IB2 No GSM155661
CC553 Cervical cancer Gynecologic Oncology Group + (35) Yes Cervix Female 53 Poorly/undiffer IB No GSM155662
CC600 Cervical cancer Gynecologic Oncology Group + (66) No Cervix Female 55 Poorly/undiffer IB1 No GSM155663
CC701 Cervical cancer Gynecologic Oncology Group - Yes Cervix Female 26 Poorly/undiffer IB2 Yes GSM155664

Total number of rows: 84

Table truncated, full table size 8 Kbytes.




Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE6791_RAW.tar 444.1 Mb (http)(custom) TAR (of CEL, EXP)

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap